Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Kalkine 0
countryflagAU

PharmAust Ltd

Healthcare AU PAA

NoneAUD
-(-%)

Last update at 2025-02-27T06:20:47.383337Z

Day Range

--
LowHigh

52 Week Range

0.150.43
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap111.93M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-5.81528M
  • Revenue TTM0.84M
  • Revenue Per Share TTM0.002
  • Gross Profit TTM 2.48M
  • Diluted EPS TTM-0.02

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -6.21156M -1.70821M -1.33731M -1.36199M -1.61704M
Minority interest - - - - -
Net income -6.21156M -1.70821M -1.33731M -1.36199M -1.66486M
Selling general administrative 4.30M 4.74M 3.85M 4.24M 4.39M
Selling and marketing expenses - - - - -
Gross profit 2.04M 3.07M 1.92M 2.95M 3.34M
Reconciled depreciation 0.33M 0.31M 0.30M 0.27M 0.17M
Ebit -2.62422M -1.61970M -1.25832M -1.24350M -1.56922M
Ebitda -2.29767M -1.30477M -0.95835M -0.96886M -1.39679M
Depreciation and amortization 0.33M 0.31M 0.30M 0.27M 0.17M
Non operating income net other - - - - -
Operating income -3.25377M -1.62023M -1.27304M -1.24679M -1.56922M
Other operating expenses -7.35786M -5.50172M -4.47933M -4.87459M 5.93M
Interest expense 0.08M 0.09M 0.08M 0.12M 0.05M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.08M 0.00054M 0.01M 0.12M 0.05M
Net interest income -0.00084M -0.08797M -0.06427M -0.11850M -0.03002M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 1.08M 1.22M 1.60M 1.05M 0.05M
Total revenue 2.82M 3.38M 2.14M 3.20M 3.67M
Total operating expenses 5.74M 5.82M 4.71M 5.12M 5.60M
Cost of revenue 0.79M 0.31M 0.23M 0.25M 0.33M
Total other income expense net -2.51012M 1.13M 1.52M 0.93M -0.04782M
Discontinued operations - - - - -
Net income from continuing ops -6.21156M -1.70821M -1.33731M -1.36199M -1.55122M
Net income applicable to common shares -6.21156M -1.70821M -1.33731M -1.36199M -1.55122M
Preferred stock and other adjustments - - - - -
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Total assets 11.12M 6.13M 10.08M 10.95M 10.75M
Intangible assets - 3.11M 3.11M 3.14M 3.11M
Earning assets - - - - -
Other current assets 1.26M 0.08M 0.02M 0.02M 0.03M
Total liab 0.90M 2.24M 2.23M 2.07M 2.22M
Total stockholder equity 10.23M 3.89M 7.84M 8.88M 8.53M
Deferred long term liab - - - - -
Other current liab 0.07M 0.42M 0.56M 0.35M 0.50M
Common stock 69.94M 57.63M 55.34M 55.33M 53.77M
Capital stock 69.94M 57.63M 55.34M 55.33M 53.77M
Retained earnings -64.13204M -56.45889M -50.24733M -48.53912M -47.20181M
Other liab - 0.00334M 0.03M 0.03M 0.04M
Good will - - - - -
Other assets - 0.32M - - -
Cash 9.71M 2.71M 2.42M 3.02M 2.88M
Cash and equivalents - - - - -
Total current liabilities 0.90M 1.35M 1.17M 0.91M 1.10M
Current deferred revenue - -0.15845M -0.34807M -0.14664M -0.31013M
Net debt -9.71411M -1.65698M -1.03055M -1.74226M -1.40864M
Short term debt - 0.16M 0.35M 0.15M 0.35M
Short long term debt - - 0.21M 0.04M 0.18M
Short long term debt total - 1.05M 1.39M 1.28M 1.47M
Other stockholder equity - -1.17382M -5.09661M -6.78732M -6.57062M
Property plant equipment - 0.00164M 3.24M 3.45M 3.57M
Total current assets 11.12M 3.02M 3.73M 4.36M 4.07M
Long term investments - - - - -
Net tangible assets - 0.78M 4.73M 5.74M 5.42M
Short term investments 0.00422M 0.02M 0.00422M 0.00422M 0.00429M
Net receivables 0.15M 0.15M 0.19M 0.24M 0.30M
Long term debt - - - 0.00000M 0.04M
Inventory - 0.09M 1.04M 1.01M 0.86M
Accounts payable 0.83M 0.93M 0.60M 0.56M 0.56M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 4.42M 2.72M 2.75M 2.09M 1.96M
Additional paid in capital - - - - -
Common stock total equity - - - - 53.77M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - -3.10912M -6.34747M -6.59697M -6.67619M
Deferred long term asset charges - - - - -
Non current assets total 0.00000M 3.11M 6.35M 6.60M 6.68M
Capital lease obligations - 1.05M 1.17M 1.24M 1.25M
Long term debt total - 0.89M 1.04M 1.13M 1.12M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -0.03493M -0.04338M -0.13804M -0.03023M -0.14672M
Change to liabilities 0.32M 0.04M 0.00201M -0.11602M 0.06M
Total cashflows from investing activities -0.03493M -0.04338M -0.13804M -0.03023M -0.14672M
Net borrowings -0.35433M 0.05M -0.32073M -0.29402M -0.10103M
Total cash from financing activities 1.89M 0.77M 1.22M 2.09M 1.92M
Change to operating activities -0.03668M 0.00850M -0.00706M 0.07M -0.04138M
Net income -6.21156M -1.70821M -1.33731M -1.36199M -1.66486M
Change in cash 0.29M -0.60465M 0.14M 0.79M 0.22M
Begin period cash flow 2.42M 3.02M 2.88M 2.09M 1.88M
End period cash flow 2.71M 2.42M 3.02M 2.88M 2.09M
Total cash from operating activities -1.56418M -1.33226M -0.93797M -1.27000M -1.55401M
Issuance of capital stock 2.24M 0.72M 1.54M 2.38M 2.02M
Depreciation 0.33M 0.31M 0.30M 0.27M 0.17M
Other cashflows from investing activities -0.00017M 0.00000M -0.03632M - -
Dividends paid - - - - -
Change to inventory -0.00422M -0.03492M -0.15050M -0.24575M -0.03780M
Change to account receivables -0.04090M 0.06M 0.06M -0.03884M -0.01049M
Sale purchase of stock 2.24M 0.72M 1.54M 2.38M 2.02M
Other cashflows from financing activities -0.03493M 0.21M -0.13804M -0.03023M -0.14672M
Change to netincome 4.08M -0.01382M 0.20M 0.14M -0.14174M
Capital expenditures 0.03M 0.04M 0.14M 0.03M 0.15M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.04511M 0.02M -0.09477M -0.28459M 0.69M
Stock based compensation -0.01001M -0.04634M 0.16M 0.05M -
Other non cash items 4.32M 0.06M 0.10M -0.18265M 1.38M
Free cash flow -1.59911M -1.37564M -1.07600M -1.30023M -0.14672M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
PAA
PharmAust Ltd		 - -% - - - 132.97 8.66 8.72 -22.5865
CSL
CSL Ltd		 1.50 0.62% 242.50 28.55 32.05 7.64 4.03 5.80 18.01
TLX
Telix Pharmaceuticals Ltd		 0.40 1.67% 24.35 177.75 56.82 10.64 14.57 10.40 88.05
MSB
Mesoblast Ltd		 0.01 0.93% 1.63 - 454.55 369.57 2.90 67.90 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 0.20 1.41% 14.40 12.99 78.12 8.25 4.61 7.03 8.53

Reports Covered

Stock Research & News

View All

Profile

PharmAust Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases in Switzerland, Australia, the United States, and internationally. The company develops drug discovery intellectual property for the treatment of various cancers and neurological diseases. Its lead candidate is Monepantel (MPL), a small molecule drug which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, as well as to treat other neurodegenerative diseases, such as Alzheimer's and Parkinson's disease. PharmAust Limited was incorporated in 2000 and is based in Melbourne, Australia.

PharmAust Ltd

96-100 Albert Road, Melbourne, VIC, Australia, 3205

Key Executives

Name Title Year Born
Dr. Roger Aston B.Sc., BSc (Hons), Ph.D. Exec. Chairman & Acting CEO 1956
Mr. Sam Michael Wright A.C.I.S., ACIS, AFin, DipAcc, M.A.I.C.D., MAICD Fin. Director, Company Sec. & Non-Exec. Director 1978
Mr. Robert Charles Bishop LLB (Hons) Exec. Director NA
Ms. Fiona Milner Gen. Mang. of Epichem Pty Ltd NA
Dr. Gary Pitt Head of Chemistry NA
Dr. James Rixson Head of Production NA
Mr. Sam Michael Wright A.C.I.S., ACIS, AFin, DipAcc, M.A.I.C.D., MAICD Finance Director, Company Secretary & Non-Executive Director 1978
Mr. Robert Charles Bishop LLB (Hons) Executive Director NA
Ms. Fiona Milner General Manager of Epichem Pty Ltd NA
Dr. Michael Thurn Ph.D. CEO & Director NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.